A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancer
Phase 2
Recruiting
- Conditions
- HER2-positive, recurrent, non-small cell lung cancer
- Registration Number
- JPRN-UMIN000019446
- Lead Sponsor
- Okayama University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
There are no special instruction regarding this section.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of biomarkers related to efficacy of or resistance to T-DM1 for patients with HER2-positive non-small cell lung cancer
- Secondary Outcome Measures
Name Time Method